ABL Diagnostics Submits Takeover Bid for Texcell Amid Bankruptcy Proceedings
On Tuesday, June 9, ABL Diagnostics submitted a takeover offer to the Evry Commercial Court to acquire the business and assets of Texcell, a company specializing in viral safety testing and immunology services. This move is part of the molecular diagnostics group's external growth strategy.
ABL Diagnostics (Euronext: ABLD) has submitted its offer under Article L. 642-1 of the French Commercial Code, as part of the bankruptcy proceedings involving Texcell before the Evry Commercial Court. The acquisition is subject to the court's approval and the outcome of ongoing insolvency proceedings. At this stage, there is no certainty about the outcome of these proceedings. The group, based in Woippy, Moselle and specializing in molecular diagnostic solutions and clinical sample management, is thus looking to explore external growth opportunities that complement its current portfolio.
Projected Growth by 2026
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
This initiative is part of the group's development strategy to explore external growth opportunities that complement its portfolio. The operation could help consolidate this trajectory by enhancing the group's capabilities in adjacent segments. ABL Diagnostics currently markets a range of products including PCR tests (UltraGene), DNA sequencing genotyping (DeepChek), as well as real-time syndromic solutions and clinical sample collection kits.
SectorSanté · Biotechnologies · Vaccins et laboratoires de recherche›Biotechnologie
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
